Compugen Ltd (CGEN)

Price$2.82

Favorite Metrics

Price vs S&P 500 (26W)43.69%

Price vs S&P 500 (4W)25.43%

Market Capitalization$266.64M

P/E Ratio (Annual)7.54x

All Metrics

P/CF (Annual)8.43x

Book Value / Share (Quarterly)$1.09

P/TBV (Annual)0.73x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)113.28%

Cash Flow / Share (Quarterly)$0.33

Price vs S&P 500 (YTD)80.18%

Gross Margin (TTM)87.29%

Net Profit Margin (TTM)48.57%

EPS (TTM)$0.36

10-Day Avg Trading Volume0.57M

EPS Excl Extra (TTM)$0.36

Revenue Growth (5Y)105.20%

EPS (Annual)$0.38

ROI (Annual)34.40%

Gross Margin (Annual)87.29%

Net Profit Margin (5Y Avg)-215.55%

Cash / Share (Quarterly)$1.54

P/E Basic Excl Extra (TTM)7.54x

Revenue Growth QoQ (YoY)4477.29%

P/E Normalized (Annual)7.54x

ROA (Last FY)22.57%

Revenue Growth TTM (YoY)161.14%

EBITD / Share (TTM)$0.34

ROE (5Y Avg)-19.11%

Operating Margin (TTM)43.05%

Cash Flow / Share (Annual)$0.33

P/B Ratio2.60x

P/B Ratio (Quarterly)1.39x

Net Income / Employee (Annual)$1

EV / Revenue (TTM)2.42x

Net Interest Coverage (TTM)0.50x

ROA (TTM)29.68%

EV / EBITDA (TTM)5.54x

EPS Incl Extra (Annual)$0.38

Current Ratio (Annual)6.56x

Quick Ratio (Quarterly)6.56x

3-Month Avg Trading Volume0.41M

52-Week Price Return94.48%

EV / Free Cash Flow (Annual)5.62x

P/E Incl Extra (TTM)7.54x

Revenue / Employee (TTM)$1

Tangible BV / Share (Quarterly)$0.60

P/S Ratio (Annual)3.66x

Asset Turnover (Annual)0.46x

52-Week High$2.94

Operating Margin (5Y Avg)-221.06%

EPS Excl Extra (Annual)$0.38

CapEx CAGR (5Y)12.47%

Tangible BV CAGR (5Y)21.53%

26-Week Price Return52.43%

Quick Ratio (Annual)6.47x

13-Week Price Return42.42%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.56x

Enterprise Value$176.043

Revenue / Share Growth (5Y)98.61%

Asset Turnover (TTM)0.61x

Book Value / Share Growth (5Y)-5.36%

Revenue / Employee (Annual)$1

Inventory Turnover (Annual)28.20x

Pretax Margin (Annual)48.65%

Cash / Share (Annual)$1.54

3-Month Return Std Dev80.14%

Gross Margin (5Y Avg)85.72%

Net Income / Employee (TTM)$1

ROE (Last FY)34.40%

Net Interest Coverage (Annual)11.00x

EPS Basic Excl Extra (Annual)$0.38

P/FCF (TTM)5.32x

Receivables Turnover (TTM)0.91x

EV / Free Cash Flow (TTM)5.62x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.36

Receivables Turnover (Annual)0.91x

ROI (TTM)55.68%

P/S Ratio (TTM)3.66x

Pretax Margin (5Y Avg)-206.79%

Revenue / Share (Annual)$0.78

Tangible BV / Share (Annual)$0.90

Price vs S&P 500 (52W)59.39%

P/E Ratio (TTM)7.54x

Year-to-Date Return84.31%

5-Day Price Return2.17%

EPS Normalized (Annual)$0.38

ROA (5Y Avg)-13.38%

Net Profit Margin (Annual)48.57%

Month-to-Date Return32.39%

EBITD / Share (Annual)$0.34

Operating Margin (Annual)43.05%

P/CF (TTM)8.43x

ROI (5Y Avg)-19.11%

P/E Excl Extra (TTM)7.54x

LT Debt / Equity (Quarterly)0.03x

EPS Basic Excl Extra (TTM)$0.36

P/TBV (Quarterly)1.06x

P/B Ratio (Annual)1.39x

Inventory Turnover (TTM)24.20x

Pretax Margin (TTM)48.65%

Book Value / Share (Annual)$1.09

Price vs S&P 500 (13W)39.56%

Beta2.85x

P/FCF (Annual)8.51x

Revenue / Share (TTM)$0.76

ROE (TTM)55.68%

52-Week Low$1.23

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.40

4.36

About

Compugen Ltd is a clinical-stage biopharmaceutical company developing cancer immunotherapies using computational drug discovery to identify novel immune targets. The company has four programs in clinical development targeting immune checkpoints and resistance pathways, including COM701, COM902, and bapotulimab, plus early-stage programs focusing on myeloid targets.